4D PHARMA
NASDAQ:
LBPS
Longevity Acquisition Corp. is in the process of merging with 4d Pharma. 4D pharma's Live Biotherapeutic Products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programs, namely a Phase I/II study of MRx0518 in combination with Keytruda (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19, and Blautix in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions, and autoimmune diseases. 4d Pharma has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.
Key Facts
Auditor
Public Listing
Domicile
HQ/Management
Location of Key Operations
IR Contact
Marcum LLP
SPAC (October 15, 2018)
British Virgin Islands
Pudong, Shanghai, China
Matthew Chen, Internal
86-21-6083-2028
Analyst Coverage
Latest News
September 17, 2021: Holding(s) in Company | 4D Pharma plc (design-portfolio.co.uk)
September 16, 2021: Holding(s) in Company | 4D Pharma plc (design-portfolio.co.uk)
September 15, 2021: 4D pharma presents two posters at ESMO Congress | 4D Pharma plc (design-portfolio.co.uk)
September 9, 2021: Participation in Upcoming Investor Conferences | 4D Pharma plc (design-portfolio.co.uk)
July 6, 2021: Publication - LBP improves activity of CAR-T | 4D Pharma plc (design-portfolio.co.uk)
June 29, 2021: Ladenburg Thalmann Healthcare Conference | 4D Pharma plc (design-portfolio.co.uk)
June 22, 2021: Conference presentation on LBP Manufacturing’ | 4D Pharma plc (design-portfolio.co.uk)
June 4, 2021: Asthma trial Part A enrolment and program update | 4D Pharma plc (design-portfolio.co.uk)
June 1, 2021: Total Voting Rights | 4D Pharma plc (design-portfolio.co.uk)
May 24, 2021: Result of AGM | 4D Pharma plc (design-portfolio.co.uk)
May 24, 2021: Update on Data for Phase II Study of Blautix | 4D Pharma plc (design-portfolio.co.uk)
May 17, 2021: Presentation of Blautix IBS Phase II at DDW 2021 | 4D Pharma plc (design-portfolio.co.uk)
April 19, 2021: 4D pharma collaborates with Parkinson's UK to establish Patient Advisory Board
April 16, 2021: Directors' Subscription for new Ordinary Shares
April 15, 2021: Annual Report and Notice of AGM
April 15, 2021: 4D pharma to Participate in Jefferies Microbiome-Based Therapeutics Summit
April 1, 2021: Final Results for the year ended 31 December 2020
March 26, 2021: Standard form for notification of major holdings
March 25, 2021: Standard form for notification of major holdings
March 22, 2021: Completion of Merger with Longevity Acquisition Corporation and admission of American Depositary Shares to trading on NASDAQ
March 18, 2021: 4D pharma and Longevity Acquisition Corporation receive shareholder approval to complete business combination
March 3, 2021: 4D Pharma to Present at Upcoming Investor Conferences in March
March 1, 2021: Exercise of Options and Total Voting Rights
March 1, 2021: 4D Pharma Appoints Paul Maier to the Board as Non-Executive Director
February 26, 2021: 4D pharma announces Posting of Circular
February 26, 2021: 4D pharma announces U.S. SEC Declares Registration Statement Effective
February 26, 2021: Definitive proxy statement relating to merger or acquisition
February 3, 2021: Longevity Acquisition Corporation Announces 4D pharma Update on Oncology Program